GMR Solutions Lowers IPO Size to $479 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 12 2026
0mins
Source: renaissancecapital
- IPO Size Adjustment: GMR Solutions has lowered its upcoming IPO size to $479 million, planning to offer 31.9 million shares at $15 each, which represents a 36% decrease from the previous price range of $22 to $25.
- Market Value Decline: With the revised pricing, GMR Solutions will command a fully diluted market value of $3.8 billion, reflecting a 31% drop from earlier expectations, potentially impacting investor confidence and market performance.
- Business Background: Founded in 2018, GMR Solutions specializes in emergency medical services and out-of-hospital care both in the U.S. and internationally, reporting $5.7 billion in revenue for the 12 months ending December 31, 2025, indicating strong performance in the healthcare sector.
- Listing Plans: The company plans to list on the NYSE under the ticker GMRS during the week of May 11, 2026, with joint bookrunners including J.P. Morgan, KKR, and BofA Securities among other prominent investment banks.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GMRS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GMRS
Wall Street analysts forecast GMRS stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 12.010
Low
Averages
High
Current: 12.010
Low
Averages
High

No data
About GMRS
GMR Solutions Inc. is a provider of emergency medical services and integrated providers of essential alternate-site, out-of-hospital care in the United States and mobile clinical practice groups globally. It maintains longstanding relationships across the healthcare ecosystem, serving local communities, health systems, payors, public health and local, state and federal agencies. Its emergent care services include rapid, clinically appropriate responses, lifesaving critical interventions and, when necessary, transport to the next site of care. Its non-emergent care services include scheduled and non-emergency patient care. Together with its professional pilots, mechanics, communications specialists and other operational support roles, it delivers comprehensive care across a range of time-sensitive patient conditions, from cardiac arrests, strokes and significant traumatic injuries to acute behavioral health episodes, toxic exposures, and emergent in-the-field newborn deliveries.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Parabilis Debut Performance: Parabilis Medicines Inc. saw its stock surge 58% on its Nasdaq debut, pricing 33.5 million shares at $20 each, with expected gross proceeds of approximately $670 million, indicating strong market demand for its innovative drug candidates.
- Clover Health Legal Victory: Clover Health Investments Corp. achieved a legal victory against the U.S. Department of Health and Human Services, upgrading its PPO plan's star rating from 3.5 to 4.5, with projected total revenues for 2026 between $2.81 billion and $2.92 billion, reflecting a 49% year-over-year growth.
- Shoulder Innovations Growth: Shoulder Innovations, Inc. reported a net revenue of $16.7 million for Q1, a 65% increase year-over-year, and expects full-year 2026 revenues between $65 million and $68 million, representing a growth of 37% to 44%, showcasing its strong position in the shoulder surgical market.
- Myomo Stock Surge: Myomo Inc.'s stock rose over 17%, with projected Q2 2026 revenues between $10.3 million and $10.8 million, compared to $9.7 million in Q2 2025, reflecting increasing market demand for its wearable medical robotics products.
See More
- Regentis Stock Surge: Regentis Biomaterials Ltd. shares soared over 88% as the company prepares to commence European Surgeon Training for GelrinC in Q3 2026, accelerating its commercialization efforts in knee cartilage repair and enhancing its competitive edge in the market.
- Eloxx Uplisting Success: Eloxx Pharmaceuticals Inc. saw its stock rise more than 77% after uplisting to Nasdaq, with plans to issue 2.975 million shares at $11.00 each, expected to generate $66 million in revenue, supporting its clinical trials for Alport syndrome treatment.
- Alignment Healthcare Gains: Alignment Healthcare Inc. shares increased over 25% following disclosures of RSU grants to executives, with projected Q2 2026 revenues between $1.295 billion and $1.315 billion, indicating strong growth potential in the healthcare sector.
- Cartesian Strategic Licensing: Cartesian Therapeutics Inc. inked a strategic licensing deal with WestGene Biopharma to advance CAR-T therapies for autoimmune diseases, with a Phase 1 trial expected to start in 2H 2026, potentially driving innovation in this therapeutic area.
See More
- BofA Upgrades Brown-Forman: Bank of America upgraded Brown-Forman from underperform to neutral, citing better-than-expected Q4/FY26 results and consistent sales delivery, indicating a more constructive outlook that could enhance market performance.
- Goldman Sachs Upgrades W.R. Berkley: Goldman Sachs upgraded W.R. Berkley from neutral to buy, believing that sustainable underwriting activity will yield long-term benefits for investors, reflecting stability and growth potential in the insurance sector.
- Morgan Stanley Initiates Cerebras: Morgan Stanley initiated coverage on Cerebras with an overweight rating, highlighting unique demand for low-latency inference solutions that is driving growth, with projected revenues of $6 billion by 2028 indicating a strong market outlook.
- UBS Upgrades Cummins: UBS upgraded Cummins from neutral to buy and raised the price target to $850, anticipating double-digit growth in its power division and the rollout of new engines to drive earnings growth over the next two years.
See More
- Record Fundraising: Thirteen IPOs raised a total of $11.5 billion in May, marking the highest monthly proceeds since November 2021, indicating a robust market recovery and renewed investor confidence.
- Large Deals Dominate: AI chipmaker Cerebras led the market with a $5.6 billion deal, while geothermal energy developer Fervo and data center REIT Blackstone Digital Infrastructure Trust also raised over $1 billion each, highlighting strong demand in AI-related sectors.
- Strong IPO Performance: Traditional IPOs averaged a 5% return from their offer prices, with about half closing above their issue prices, reflecting positive market sentiment towards new listings, particularly with Fervo and BXDC showing strong first-day gains.
- Optimistic Future Outlook: With new filings from companies like SpaceX, more IPO transactions are expected in the coming months as the market broadens, and strong returns alongside a solid pipeline set the stage for a busy IPO calendar ahead.
See More
- Strong Financial Performance: GMR Solutions Inc. reported a Q1 2026 GAAP EPS of $0.28 with revenues of $1.46 billion, net income of $106.3 million, and adjusted EBITDA of $305.1 million, indicating robust growth in both revenue and profitability.
- Strong Liquidity Position: As of March 31, 2026, the company maintained a liquidity position exceeding $1.1 billion, comprising $426.1 million in cash and cash equivalents and approximately $691.6 million in available borrowing capacity, ensuring financial flexibility for future investments and operations.
- Preferred Stock Redemption: On March 6, 2026, GMR redeemed 189,050 shares of preferred stock for an aggregate redemption price of approximately $250 million, which not only optimizes the capital structure but may also enhance value for common shareholders.
- 2026 Financial Guidance: The company established guidance for 2026, projecting net revenue between $5.89 billion and $6.18 billion, with adjusted EBITDA expected to range from $1.135 billion to $1.195 billion, reflecting confidence in future performance and positive market demand.
See More
- Significant Revenue Growth: GMR Solutions reported net revenue of $1.4576 billion for Q1 2026, a 6.6% increase from $1.3674 billion in Q1 2025, indicating strong market demand in the emergency medical services sector and reinforcing its industry leadership.
- Substantial Net Income Increase: The company achieved a net income of $106.3 million in Q1, up 179.7% year-over-year, reflecting GMR's success in cost control and operational efficiency, which enhances investor confidence in its long-term growth potential.
- Adjusted EBITDA Improvement: Adjusted EBITDA reached $305.1 million, a 9.7% increase compared to $278.1 million in the previous year, demonstrating ongoing enhancements in profitability that could attract more investment and support future expansion plans.
- Strong Liquidity Position: As of March 31, 2026, GMR maintained a liquidity position exceeding $1.1 billion, including $426.1 million in cash and cash equivalents, ensuring financial flexibility for future investments and operations.
See More











